Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus PENTIDS 250.
OMNIPEN-N vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
250 mg orally every 8 hours.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic